The transmembrane protease serine 2 gene (TMPRSS2) is involved in gene fusions with ERG, ETV1 or ETV4 in prostate cancer. It has been reported that the expression of the TMPRSS2-ERG fusion gene is a strong prognostic factor for the risk of prostate cancer recurrence in prostate cancer patients treated by surgery. The TMPRSS2-ERG rearrangement probe is optimized to detect the deletion between TMPRSS2 and ERG at 21q22 associated with the TMPRSS2-ERG fusion in a triple-color deletion assay. It also detects translocations involving the TMPRSS2 region such as ETV1 t(7;21), or ETV4 t(17;21).
Perner et al, 2006, Cancer Res 66; 8337-8341.
Hermans et al, 2006, Cancer Res 66; 10658-10663.
Attard et al, 2008, Oncogene 27; 253-263.